Photodynamic therapy for malignant pleural mesothelioma
Schouwink, J.H.

Citation for published version (APA):

General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: http://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.
Abbreviations

CHAPTER

I Introduction and outline of the thesis

II Photodynamic therapy for malignant pleural mesothelioma: preclinical studies for optimization of treatment protocols.

*Photochemistry and Photobiology 2001; 73(4): 410-417*

III Oxygen depletion during and after mTHPC mediated Photodynamic Therapy in RIF1 and H-MESO1 tumors.

*Submitted for publication*

IV Normal tissue damage due to intrathoracic mTHPC mediated Photodynamic Therapy: preclinical studies in minipigs and rats.

*To be submitted*

V Prognostic value of the serum tumour markers Cyfra 21-1 and Tissue Polypeptide Antigen in malignant mesothelioma.

*Lung Cancer 1999; 25: 25-32*

VI The value of CT scan and cervical mediastinoscopy in the preoperative assessment of patients with malignant pleural mesothelioma.

*To be submitted*

VII Intra-operative Photodynamic Therapy after pleuropneumonectomy in patients with malignant pleural mesothelioma: dose finding and toxicity results.

*Chest 2001; 120: 1167-1174*

VIII Summary and General discussion

Samenvatting en algemene beschouwing

Dankwoord

Curriculum Vitae
Abbreviations
CA 125  Carcino Antigen 125
CCD  Coupled Charge Device
CEA  Carcino Embryonic Antigen
CM  Cervical Mediastinoscopy
CT  Computer Tomography
CUSA  Cavitron Ultrasound Surgical Aspirator
DHE  Di-haematoporphyrinether
EF3  [2-(2-nitroimidazol-1[H]-yl)-N-(3,3,3-trifluoropropyl)acetamide]
FCS  Fetal Calf Serum
FDG  Fluoro-deoxyglucose
FEV1  Forced Expiratory Volume in 1 second
H&E  Hematoxylin & Eosin
H-MESO1  Human Mesothelioma xenograft 1
ICU  Intensive Care Unit
IMIG  International Mesothelioma Interest Group
IPDT  Intrathoracic Photodynamic Therapy
MM  Malignant Mesothelioma
MMMF  Man Made Mineral Fibre
MPM  Malignant Pleural Mesothelioma
MRI  Magnetic Resonance Imaging
MTHPC  meta-Tetrahydroxyphenylchlorin
MTHPP  meta-Tetrahydroxyphenylporphyrin
NSCLC  Non Small Cell Lung Carcinoma
PBS  Phosphate Buffered Saline
PDT  Photodynamic Therapy
PEEP  Positive End Expiratory Pressure
PET  Positron Emission Tomography
RIF1  Radiation Induced Fibrosarcoma 1
RM-ANOVA  Repeated Measurements Analysis of Variance
SD  Sprague Dawley
TPA  Tissue Polypeptide Antigen
WHO  World Health Organisation